BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pilc A, Machaczka A, Kawalec P, Smith JL, Witkin JM. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opin Drug Discov 2022;17:1131-46. [PMID: 35934973 DOI: 10.1080/17460441.2022.2111415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chaki S, Watanabe M. Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system. Neuropharmacology 2023;223:109348. [PMID: 36423706 DOI: 10.1016/j.neuropharm.2022.109348] [Reference Citation Analysis]
2 Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 2023;226:109422. [PMID: 36646310 DOI: 10.1016/j.neuropharm.2023.109422] [Reference Citation Analysis]
3 Samojedny S, Czechowska E, Pańczyszyn-trzewik P, Sowa-kućma M. Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders. IJMS 2022;23:11423. [DOI: 10.3390/ijms231911423] [Reference Citation Analysis]